Scientists test Dual-Attack strategy for Tough-to-Treat blood cancer
NCT ID NCT06222580
Summary
This early-stage study is testing the safety and finding the best dose of a new two-drug combination (SNDX-5613 and gilteritinib) for adults with a specific form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The drugs work together to block two different signals that tell the cancer cells to grow. The main goals are to see if the combination is safe and tolerable for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UNC Hospitals, University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 24514, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.